Biocytogen Calls 2026 Extraordinary Meeting to Vote on New Non-Executive Director
I'm PortAI, I can summarize articles.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has announced an extraordinary general meeting on February 12, 2026, to vote on the appointment of Mr. Liu Hongkang as a non-executive director. The meeting will be held in a hybrid format to enhance shareholder participation. This decision may influence the company's board composition and governance. The current analyst rating for Biocytogen's stock (HK:2315) is a Hold, with a price target of HK$48.00 and a market cap of HK$16.99B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments